US Edition'Game Changer' for HIV Prevention in SA as Lower-Income Countries Granted Access to Breakthrough Drug
LOW- AND MIDDLE-INCOME COUNTRIES, JUL 9 – Gilead will provide its HIV prevention drug lenacapavir at no-profit price to 2 million people in low- and middle-income countries, focusing on high-incidence regions in Africa, Global Fund said.
- On July 9, a three-year agreement was finalized to provide the HIV prevention medication lenacapavir at no profit to low- and middle-income countries, including South Africa, with a health financing organization responsible for purchasing and distributing the drug.
- This agreement follows FDA approval of lenacapavir in June and aims to address the HIV epidemic despite concerns over limited licensed territories and funding uncertainties raised by Global Fund chief Peter Sands.
- Gilead will supply doses for up to 2 million people at no profit to countries eligible for Global Fund support, while negotiating prices country by country for certain middle-income nations excluded from voluntary licenses.
- Peter Sands described the agreement as a pivotal moment in the fight against HIV/AIDS, emphasizing that adequate funding and fair distribution are essential to impact the epidemic’s course, while South Africa’s top health official referred to the deal as transformative for the country.
- The deal marks a shift to introduce lenacapavir simultaneously in low-income and high-income countries, though questions remain about broader rollout plans beyond the 120 licensed countries and the impact of past foreign aid cuts.
15 Articles
15 Articles
The Global Fund, which fights AIDS, tuberculosis and malaria, announced on Wednesday the signing of an access agreement with US pharmaceutical company Gilead, manufacturer of lenacapavir, an antiviral with nearly 100% effectiveness in the prevention of HIV, to introduce it in low- and middle-income countries. “A turning point in the fight against the virus” and a “hit for global health equity”, according to those responsible for the organization.
Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries
By Deena Beasley and Jennifer Rigby (Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV
Gilead Sciences to Deliver HIV Prevention Drug to Low-Income Countries
Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income countries. Despite a lack of U.S. funding, the initiative aims to reach 2 million people over three years. The partnership seeks to combat the ongoing global HIV epidemic.
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
